FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032078191> ?p ?o ?g. }

• W3032078191 abstract "Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer that lacks expression of estrogen receptor (ER) and progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) gene. Chemotherapy remains the standard of care for TNBC treatment, but considerable patients are very resistant to chemotherapy. Mutations or aberrant upregulation of EZH2 occur frequently, and EZH2 inhibitor (EZH2i) showed some preclinic antitumor effects in TNBC.RNA-seq data of 3 TNBC cell lines either treated with 2 μM GSK343, or stably transduced with shEHZ2, compared to untreated controls (GSE112378) were analyzed by Limma R package. The Kaplan-Meier plotter (KM plotter) database was used to assess the relevance of FOSB mRNA expression to relapse-free survival (RFS) in TNBC. Cell number counting and colony formation assays were used to detect the biological effect of FOSB on the growth of TNBC cells in vitro. The effect of FOSB on TNBC tumor growth in vivo was investigated in a mice tumor xenograft model. Luciferase reporter and chromatin immunoprecipitation (Chip) assays were used to determine the regulatory roles of C/EBPβ on FOSB expression.We found that FOSB, a member of the activator protein-1 complex, was a direct downstream target of EZH2. FOSB was significantly decreased in TNBC samples and associated with better relapse-free survival (RFS). EZH2-mediated histone 3 trimethylated on lysine 27 (H3K27me3), a marker of silent chromatin conformation, at the FOSB promoter inhibited it expression. Depletion of FOSB in TNBC cells promoted cell proliferation in vitro and tumor growth in vitro by inactivating the p53 pathway and conferred resistant to EZH2 inhibitor (EZH2i). Mechanistically, EZH2i promotes the shift from H3K27me3 to H3K27ac at the FOSB promoter, and recruits the transcription factor C/EBPβ to activate FOSB gene transcription.Together, our results suggest that EZH2-mediated epigenetic inactivation of FOSB promotes TNBC expression and demonstrate that reactivation of FOSB expression by C/EBPβ underlies the anti-TNBC action of EZH2is." @default.
• W3032078191 created "2020-06-05" @default.
• W3032078191 creator A5007949406 @default.
• W3032078191 creator A5018093835 @default.
• W3032078191 creator A5018346151 @default.
• W3032078191 creator A5049341927 @default.
• W3032078191 creator A5057931640 @default.
• W3032078191 creator A5088926464 @default.
• W3032078191 date "2020-05-19" @default.
• W3032078191 modified "2023-10-14" @default.
• W3032078191 title "EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress" @default.
• W3032078191 cites W1977199336 @default.
• W3032078191 cites W1977709885 @default.
• W3032078191 cites W1985003152 @default.
• W3032078191 cites W1996487270 @default.
• W3032078191 cites W2024373518 @default.
• W3032078191 cites W2026031571 @default.
• W3032078191 cites W2044702943 @default.
• W3032078191 cites W2053421436 @default.
• W3032078191 cites W2061096783 @default.
• W3032078191 cites W2067427748 @default.
• W3032078191 cites W2070604281 @default.
• W3032078191 cites W2079298594 @default.
• W3032078191 cites W2097255042 @default.
• W3032078191 cites W2100365251 @default.
• W3032078191 cites W2100630390 @default.
• W3032078191 cites W2125496315 @default.
• W3032078191 cites W2131994307 @default.
• W3032078191 cites W2149336004 @default.
• W3032078191 cites W2154142993 @default.
• W3032078191 cites W2158102062 @default.
• W3032078191 cites W2160689782 @default.
• W3032078191 cites W2226721679 @default.
• W3032078191 cites W2256666377 @default.
• W3032078191 cites W2259802687 @default.
• W3032078191 cites W2264682687 @default.
• W3032078191 cites W2320983896 @default.
• W3032078191 cites W2402636472 @default.
• W3032078191 cites W2481513060 @default.
• W3032078191 cites W2509400140 @default.
• W3032078191 cites W2522895022 @default.
• W3032078191 cites W2563365723 @default.
• W3032078191 cites W2742987737 @default.
• W3032078191 cites W2892042921 @default.
• W3032078191 cites W2905560860 @default.
• W3032078191 cites W2911646969 @default.
• W3032078191 cites W2914809873 @default.
• W3032078191 cites W2925415367 @default.
• W3032078191 doi "https://doi.org/10.1186/s12935-020-01260-5" @default.
• W3032078191 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7236314" @default.
• W3032078191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32477007" @default.
• W3032078191 hasPublicationYear "2020" @default.
• W3032078191 type Work @default.
• W3032078191 sameAs 3032078191 @default.
• W3032078191 citedByCount "14" @default.
• W3032078191 countsByYear W30320781912020 @default.
• W3032078191 countsByYear W30320781912021 @default.
• W3032078191 countsByYear W30320781912022 @default.
• W3032078191 countsByYear W30320781912023 @default.
• W3032078191 crossrefType "journal-article" @default.
• W3032078191 hasAuthorship W3032078191A5007949406 @default.
• W3032078191 hasAuthorship W3032078191A5018093835 @default.
• W3032078191 hasAuthorship W3032078191A5018346151 @default.
• W3032078191 hasAuthorship W3032078191A5049341927 @default.
• W3032078191 hasAuthorship W3032078191A5057931640 @default.
• W3032078191 hasAuthorship W3032078191A5088926464 @default.
• W3032078191 hasBestOaLocation W30320781911 @default.
• W3032078191 hasConcept C104317684 @default.
• W3032078191 hasConcept C121608353 @default.
• W3032078191 hasConcept C150194340 @default.
• W3032078191 hasConcept C167227067 @default.
• W3032078191 hasConcept C2777099045 @default.
• W3032078191 hasConcept C2780110267 @default.
• W3032078191 hasConcept C50171091 @default.
• W3032078191 hasConcept C502942594 @default.
• W3032078191 hasConcept C530470458 @default.
• W3032078191 hasConcept C54355233 @default.
• W3032078191 hasConcept C55493867 @default.
• W3032078191 hasConcept C62112901 @default.
• W3032078191 hasConcept C86803240 @default.
• W3032078191 hasConceptScore W3032078191C104317684 @default.
• W3032078191 hasConceptScore W3032078191C121608353 @default.
• W3032078191 hasConceptScore W3032078191C150194340 @default.
• W3032078191 hasConceptScore W3032078191C167227067 @default.
• W3032078191 hasConceptScore W3032078191C2777099045 @default.
• W3032078191 hasConceptScore W3032078191C2780110267 @default.
• W3032078191 hasConceptScore W3032078191C50171091 @default.
• W3032078191 hasConceptScore W3032078191C502942594 @default.
• W3032078191 hasConceptScore W3032078191C530470458 @default.
• W3032078191 hasConceptScore W3032078191C54355233 @default.
• W3032078191 hasConceptScore W3032078191C55493867 @default.
• W3032078191 hasConceptScore W3032078191C62112901 @default.
• W3032078191 hasConceptScore W3032078191C86803240 @default.
• W3032078191 hasIssue "1" @default.
• W3032078191 hasLocation W30320781911 @default.
• W3032078191 hasLocation W30320781912 @default.
• W3032078191 hasLocation W30320781913 @default.
• W3032078191 hasLocation W30320781914 @default.
• W3032078191 hasLocation W30320781915 @default.
• W3032078191 hasLocation W30320781916 @default.

• next